4//SEC Filing
Kirchgraber Paul R 4
Accession 0001127602-23-011750
CIK 0000920148other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 10:13 AM ET
Size
6.2 KB
Accession
0001127602-23-011750
Insider Transaction Report
Form 4
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
- Award
Common Stock
2023-03-30+6,763→ 15,832 total - Tax Payment
Common Stock
2023-03-30$224.70/sh−2,886$648,484→ 12,946 total
Footnotes (2)
- [F1]Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022.
- [F2]Stock withholding to satisfy tax withholding obligations.
Documents
Issuer
LABORATORY CORP OF AMERICA HOLDINGS
CIK 0000920148
Entity typeother
Related Parties
1- filerCIK 0001791393
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 10:13 AM ET
- Size
- 6.2 KB